IGF1 and autism: Recent studies in cells derived from patients with autism [48] and in a clinical case with RTT treated with two cycles of IGF1 [49] suggested that prolonged treatment with IGF1 may not be ideal to produce positive benefits, at least as measured in terms of severity scores and clinical evaluation.